Nivolumab: tested in a combination
680 studies: another drug in the study is under test too. Page 5 of 7. Open to participants first (135), then studies with results posted, then the rest; newest registration first within each.
- A Study to Assess Relatlimab and Nivolumab Fixed-dose Combination in Chinese Participants With Advanced Solid TumorsCompletedNCT05134948Phase 1/2Report a problem
- Immunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer.TerminatedNCT05116917Phase 2Report a problem
- Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal MelanomaCompletedNCT05089370Phase 1/2Report a problem
- Investigator-initiated Pilot Study to Investigate the Efficacy and Safety of Immuncell-LC in Combination With Nivolumab (Opdivo) in Subjects With Advanced or Recurrent Gastric CancerStatus unknownNCT05053295Not applicableReport a problem
- A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line TherapyWithdrawnNCT05039736Phase 2Report a problem
- Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain MetastasesActive, not recruitingNCT05012254Phase 2Report a problem
- Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal MelanomaCompletedNCT05004025Phase 1Report a problem
- Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell CarcinomaCompletedNCT04987203Phase 3Report a problem
- Temozolomide + Nivolumab in MGMT Methylated Oesophagogastric CancerCompletedNCT04984733Phase 2Report a problem
- PET-Adapted Low-Dose Nivolumab With NICE-40 for Relapsed/Refractory Classical Hodgkin LymphomaCompletedNCT04981899Phase 2Report a problem
- Combination Immunotherapy in Rare Cancers Under InvesTigationActive, not recruitingNCT04969887Phase 2Report a problem
- Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic MelanomaTerminatedNCT04967196Phase 1Report a problem
- Study of Nivolumab-Ipilimumab and cfDNA in Lung CancerTerminatedNCT04966676Phase 2Report a problem
- Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal CancerActive, not recruitingNCT04963283Phase 2Report a problem
- Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III MelanomaActive, not recruitingNCT04949113Phase 3Report a problem
- Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial CarcinomaTerminatedNCT04940299Phase 2Report a problem
- Therapy Adapted for High Risk and Low Risk HIV-Associated Anal CancerActive, not recruitingNCT04929028Phase 2Report a problem
- REduced Frequency ImmuNE Checkpoint Inhibition in CancersStatus unknownNCT04913025Phase 2Report a problem
- Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma PatientsActive, not recruitingNCT04863885Phase 1/2Report a problem
- Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 InhibitorActive, not recruitingNCT04831320Phase 2Report a problem
- SARC038: Phase 2 Study of Regorafenib and Nivolumab in OsteosarcomaActive, not recruitingNCT04803877Phase 2Report a problem
- Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot StudyTerminatedNCT04801966Not applicableReport a problem
- Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic AdenocarcinomaCompletedNCT04787991Phase 1Report a problem
- Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter TransformationWithdrawnNCT04781855Phase 1Report a problem
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell LymphomaActive, not recruitingNCT04759586Phase 3Report a problem
- A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric CancerActive, not recruitingNCT04757363Phase 2Report a problem
- Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal CancerActive, not recruitingNCT04751370Phase 2Report a problem
- Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC.Active, not recruitingNCT04730544Phase 2Report a problem
- Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE TrialCompletedNCT04721301Phase 1Report a problem
- Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate CancerCompletedNCT04717154Phase 2Report a problem
- A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate CancerActive, not recruitingNCT04709276Phase 2Report a problem
- Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Resectable NSCLCActive, not recruitingNCT04699721Phase 2Report a problem
- Neoadjuvant Chemo-endocrine Therapy and Immunotherapy for Pre-menopausal Luminal B Breast Cancer PatientsCompletedNCT04659551Phase 2Report a problem
- Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary SyndromeActive, not recruitingNCT04652960Phase 1Report a problem
- Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell CarcinomaStatus unknownNCT04644432Phase 2Report a problem
- Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to SurgeryCompletedNCT04620200Phase 2Report a problem
- Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLCTerminatedNCT04610658Phase 1Report a problem
- Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS LymphomaActive, not recruitingNCT04609046Phase 1Report a problem
- Surgical Nivolumab And Ipilimumab For Recurrent GBMActive, not recruitingNCT04606316Phase 1Report a problem
- Accelerated Radio-Immunotherapy for Lung CancerCompletedNCT04577638Phase 2Report a problem
- Nivolumab+Ipilimumab+RT in MSS mCRCStatus unknownNCT04575922Phase 2Report a problem
- IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma PatientsActive, not recruitingNCT04562129Phase 2Report a problem
- Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue SarcomaActive, not recruitingNCT04551430Phase 2Report a problem
- A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine TumoursStatus unknownNCT04525638Phase 2Report a problem
- Nivolumab Combined With Anlotinib as Re-challenge Treatment in Advanced NSCLCCompletedNCT04507906Phase 1/2Report a problem
- Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal CancerStatus unknownNCT04503967Phase 2Report a problem
- Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal CancerActive, not recruitingNCT04503694Phase 2Report a problem
- Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI StudyWithdrawnNCT04500548Phase 1Report a problem
- Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma ParticipantsWithdrawnNCT04495010Phase 2Report a problem
- Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)CompletedNCT04477512Phase 1Report a problem
- Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath TumorCompletedNCT04465643Phase 1Report a problem
- A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced MelanomaActive, not recruitingNCT04464759Phase 1/2Report a problem
- Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma MetastasesCompletedNCT04463368Phase 1Report a problem
- Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop TrialActive, not recruitingNCT04462406Phase 2Report a problem
- Temozolomide, Cisplatin, and Nivolumab in People With Colorectal CancerCompletedNCT04457284Phase 2Report a problem
- Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent LymphomaTerminatedNCT04431635Phase 1Report a problem
- FOLFOX + Immunotherapy With Intrahepatic Oxaliplatin for Patients With Metastatic Colorectal CancerWithdrawnNCT04430985Phase 2Report a problem
- Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected PrimaryTerminatedNCT04429321Phase 1Report a problem
- Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCCActive, not recruitingNCT04413123Phase 2Report a problem
- Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular CarcinomaCompletedNCT04393220Phase 2Report a problem
- Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic CancerStatus unknownNCT04377048Phase 2Report a problem
- Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype MelanomaTerminatedNCT04375527Phase 2Report a problem
- Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal CancerCompletedNCT04362839Phase 1Report a problem
- Nivolumab + Ipilimumab + Radiation in MSS Pancreatic CancerActive, not recruitingNCT04361162Phase 2Report a problem
- Low-dose Gemcitabine Combined With Nivolumab for Second-line and Above Line Treatment of NSCLCStatus unknownNCT04331626Phase 4Report a problem
- Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (stage IIIB/C/D-IV M1a) Melanoma with Injectable DiseaseCompletedNCT04330430Phase 2Report a problem
- CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase InhibitionActive, not recruitingNCT04322955Phase 2Report a problem
- Evaluating Safety & Efficacy Belinostat Combo w Nivo Alone & w Ipi in Patients w Treated Metastatic/Advanced Carcinomas w ARID1A Lof MutationWithdrawnNCT04315155Phase 1Report a problem
- A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor TypesTerminatedNCT04311710Phase 1Report a problem
- Combination of Regorafenib and Nivolumab in Unresectable Hepatocellular CarcinomaCompletedNCT04310709Phase 2Report a problem
- Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung CancerActive, not recruitingNCT04310007Phase 2Report a problem
- PHP and Immunotherapy in Metastasized UMActive, not recruitingNCT04283890Phase 1/2Report a problem
- Nivolumab in Combination With Temozolomide and Radiotherapy in Children and Adolescents With Newly Diagnosed High-grade GliomaCompletedNCT04267146Phase 1/2Report a problem
- Ipilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic CancerTerminatedNCT04258150Phase 2Report a problem
- COL Immunotherapy Before Radiochimio + IpilimumabCompletedNCT04256213Not applicableReport a problem
- Nivolumab, Ipilimumab and Chemoradiation in Pancreatic Cancer.CompletedNCT04247165Phase 1/2Report a problem
- P1101 and Anti-PD1 for After Curative Surgery of Hepatitis B-related Hepatocellular CarcinomaStatus unknownNCT04233840Phase 1/2Report a problem
- Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients.Active, not recruitingNCT04229459Phase 2Report a problem
- Anlotinib Combined With Nivolumab for Non-Small Cell Lung CancerStatus unknownNCT04211896Phase 2Report a problem
- Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deletedTerminatedNCT04185311Phase 1Report a problem
- NGS as the First-line Treatment in Advanced Biliary Tract CancerCompletedNCT04172402Phase 2Report a problem
- Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING)CompletedNCT04170556Phase 1/2Report a problem
- Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid TumorsCompletedNCT04157985Phase 3Report a problem
- A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and ChemotherapyWithdrawnNCT04151563Phase 1/2Report a problem
- Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic CarcinosarcomaWithdrawnNCT04149275Phase 2Report a problem
- A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational BurdenActive, not recruitingNCT04145115Phase 2Report a problem
- Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin LymphomaActive, not recruitingNCT04134325Early Phase 1Report a problem
- Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment.Status unknownNCT04134182Phase 2Report a problem
- Nivolumab/Ipilimumab in Second Line CUP-syndromeStatus unknownNCT04131621Phase 2Report a problem
- Neoadjuvant Chemoradiotherapy With Sequential Ipilimumab and Nivolumab in Rectal CancerCompletedNCT04124601Phase 2Report a problem
- Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal CancerStatus unknownNCT04110093Phase 1/2Report a problem
- Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate CancerActive, not recruitingNCT04109729Phase 1Report a problem
- Nivolumab Plus Pemetrexed for Head and Neck Squamous Cell CarcinomaCompletedNCT04107103Phase 2Report a problem
- Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II StudyCompletedNCT04095208Phase 2Report a problem
- A Phase 2 Trial for Men With Metastatic Prostatic AdenocarcinomaCompletedNCT04090775Phase 2Report a problem
- Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm PatientsCompletedNCT04072198Phase 2Report a problem
- Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEGActive, not recruitingNCT04062656Phase 2Report a problem
- Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid CancerActive, not recruitingNCT04061980Phase 2Report a problem
- Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma HistologyCompletedNCT04046614Phase 1/2Report a problem
- Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal CancerTerminatedNCT04044430Phase 1Report a problem